

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Announcement on Progress of Application for Initial Public Offering and Listing of Shares of Shanghai Junshi Biosciences Co., Ltd.” dated 20 February 2020 published by Shanghai Junshi Biosciences Co., Ltd. on the website of the National Equities Exchange and Quotations System, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

The trading of the Company's H Shares on The Stock Exchange of Hong Kong Limited will not be affected.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 20 February 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

* For identification purpose only

Stock code: 833330

Stock short name: Junshi Bio-B

Chief Agency Broker: CICC

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

Announcement on Progress of Application for Initial Public Offering and Listing of Shares

The Company and all members of the board of directors warrant that the contents of the announcement are true, accurate and complete and that there is no false and misleading statement or material omission herein, and are severally and jointly responsible for the truthfulness, accuracy and completeness of the contents herein.

With respect to the proposed initial public offering and listing of shares by Shanghai Junshi Biosciences Co., Ltd.* (the “Company”), on 25 April 2019, the Company filed an application for listing counselling with the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission and was accepted. The counselling agency is China International Capital Corporation Limited.

I. Acceptance of Listing Counselling

On 16 September 2019, under the counselling of China International Capital Corporation Limited, the Company has obtained the acceptance from the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission.

II. Acceptance of Application by the Shanghai Stock Exchange

The Company has filed the application for the initial public offering and listing of shares on the Sci-Tech Innovation Board (STAR Market) with the Shanghai Stock Exchange (the “SSE”) and received the “Notice on the Acceptance of Application by Shanghai Junshi Biosciences Co., Ltd.* for the Initial Public Offering and Listing of Shares on the STAR Market” (Shang Zheng Ke Shen (Shou Li) [2019] No.159) (上证科审（受理）[2019]159 号《关于受理上海君实生物医药科技股份有限公司首次公开发行股票并在科创板上市申请的通知》) issued by the SSE on 26 September 2019. The application made by the Company for the initial public offering and listing of shares on the STAR Market has been officially accepted by the SSE.

Since 25 September 2019, transfer of shares of the Company on the National Equities Exchange and Quotations System has been suspended.

On 25 October 2019, the Company received the Letter of Review and Enquiry of the Application Document of Shanghai Junshi Biosciences Co., Ltd.* for the Initial Public Offering and Listing of Shares on the STAR Market (Shang Zheng Ke Shen (Shen He) [2019] No.667) (上证科审（审核）[2019]667 号《关于上海君实生物医药科技股份有限公司首次公开发行股票并在科创板上市申请文件的审核问询函》) issued by the SSE. The Company’s reply to the Letter of the First Round of Enquiry has been publicly disclosed on the SSE on 26 December 2019.

On 6 January 2020, the Company received the Letter of the Second Round of Review and Enquiry of the Application Document of Shanghai Junshi Biosciences Co., Ltd.* for the Initial Public Offering and Listing of Shares on the STAR Market (Shang Zheng Ke Shen (Shen He) [2020] No.7) (上证科审（审核）[2020] 7号《关于上海君实生物医药科技股份有限公司首次公开发行股票并在科创板上市申请文件的第二轮审核问询函》) issued by the SSE. The Company and the relevant intermediaries will in accordance with the requirements of the above-mentioned document, timely report the reply to the Letter of the Second Round of Enquiry to the SSE within the prescribed period.

III. Suspension of Review

(1) Application for Suspension of Review

As the financial statements initially filed by the Company have expired after 31 January 2020, the Company submitted the Application by Shanghai Junshi Biosciences Co., Ltd.* for the Suspension of Review Process on the Initial Public Offering and Listing of Shares on the STAR Market (《上海君实生物医药科技股份有限公司关于首次公开发行股票并在科创板上市中止审核的申请》) to the SSE on 3 February 2020.

(2) Resumption of Review

The Company has completed the update of relevant financial figures during the period of suspension of review and submitted the application for resumption of the review process to the SSE on 18 February 2020. The SSE approved the resumption of the review process on the application by the Company for the initial public offering and listing of shares on the STAR Market from 20 February 2020.

Currently, the review status regarding the application by the Company for the initial public offering and listing of shares on the STAR Market is “already enquired”.

The Company will make timely information disclosure on the progress of relevant matters in strict compliance with the laws and regulations and requirements. Investors are advised to exercise caution when making investment decisions to guard against risks.

Notice is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
20 February 2020

* For identification purpose only